# electroCore, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/electroCore, Inc.). ## Overview electroCore, Inc. develops and commercializes non-invasive bioelectronic therapies based on vagus nerve stimulation. Its core products include prescription gammaCore devices for headache and related indications, along with wellness-oriented handheld devices sold in the United States, the United Kingdom, and selected international markets. ## Products & services • Prescription gammaCore nVNS therapy • gammaCore government channel sales • Truvaga general wellness handhelds • TAC-STIM wellness/human performance devices • International distribution of nVNS products - **Prescription gammaCore therapy** (75%) — Non-invasive vagus nerve stimulation devices sold for prescribed use, especially in government and UK healthcare channels. - **Direct-to-consumer wellness devices** (17%) — Truvaga handheld products marketed for general wellness and sold through consumer channels and e-commerce. - **TAC-STIM wellness devices** (1%) — Consumer-oriented handheld devices positioned for wellness and human performance use. - **International distribution** (7%) — Sales of nVNS products outside the United States and the United Kingdom through distribution partners. - Prescription gammaCore nVNS therapy - gammaCore government channel sales - Truvaga general wellness handhelds - TAC-STIM wellness/human performance devices - International distribution of nVNS products ## Customers The company sells primarily to federal healthcare systems in the United States and to the UK National Health Service, which use gammaCore through prescription and procurement channels. It also serves individual consumers through Truvaga and TAC-STIM, and uses distribution partners to reach selected international markets. The customer base is shaped by reimbursement, procurement portals, and direct-to-consumer e-commerce access. - **U.S. federal healthcare systems** (primary) — VA, DoD, MHS and IHS facilities buy gammaCore for covered patients through federal procurement channels. - **UK National Health Service** (primary) — NHS buyers use prescription gammaCore under funding and catalog arrangements for cluster headache treatment. - **Direct-to-consumer wellness buyers** (secondary) — Consumers purchase Truvaga and TAC-STIM for general wellness and human performance use. - **International distribution partners** (secondary) — Partners buy or distribute nVNS products in selected territories outside the U.S. and UK. - U.S. federal healthcare systems buying through VA and DoD channels - UK NHS and related public healthcare buyers - Individual consumers purchasing wellness devices online - International distributors serving local healthcare markets - Physicians and facilities that dispense prescription gammaCore ## Geography The company’s commercial footprint is centered in the United States and the United Kingdom, with the U.S. federal channel and NHS representing the most important markets. It also sells through distribution partners in selected territories outside these core markets. Geography matters because reimbursement, procurement portals, and regulatory clearance differ materially by country and channel. - **United States** (88%) — Estimated from product sales mix and disclosure that VA comprised 70.3% of quarterly revenue. - **United Kingdom** (5.3%) — Disclosed as sales under the UK Med Tech Funding Mandate for the quarter. - **Outside the United States and United Kingdom** (6.7%) — Residual international revenue disclosed in product sales table. - United States is the main market, especially the federal healthcare channel - United Kingdom is a core market through NHS and MTFM arrangements - Selected non-U.S. territories are served through distribution partners - Government procurement portals shape U.S. channel access and timing - Country-specific reimbursement and guidance affect adoption and pricing ## Strategy electroCore is focused on expanding prescription gammaCore within federal healthcare and the UK public system while broadening access through additional reimbursement, cash-pay, and direct-to-consumer channels. It is also extending its product set into wellness and human performance devices and using distribution partners to reach more international markets. The strategy is designed to reduce dependence on any single channel while leveraging the same non-invasive neuromodulation platform. - **Expand federal channel sales** (short-term) — The VA and related federal systems are the largest revenue source and provide repeat procurement access. - **Protect and extend UK reimbursement access** (short-term) — NHS listing and funding support are important for prescription gammaCore adoption in the UK. - **Grow wellness and direct-to-consumer products** (medium-term) — Consumer products diversify revenue beyond prescription reimbursement and government procurement. - **Broaden international distribution** (medium-term) — Selected territories outside the U.S. and UK can extend the platform without building full direct sales coverage. - Deepen penetration in VA and other federal healthcare channels - Maintain and extend NHS access through funding and catalog programs - Expand Truvaga and TAC-STIM through direct-to-consumer channels - Use distribution partners to broaden international reach - Leverage the same nVNS platform across medical and wellness uses ## Risks The business depends heavily on a small number of government and public healthcare buyers, so procurement changes, reimbursement decisions, or guidance updates can materially affect sales. It also faces commercialization risk in consumer channels, where e-commerce platform policies, competition, and regulatory classification can disrupt access. As a development-stage medical device company with recurring losses, it remains exposed to financing, covenant, and execution risk as it scales its product mix. - **Customer concentration in federal and UK public healthcare channels** [high] — A large share of revenue comes from a few buyers and procurement systems, so contract or policy changes can quickly affect sales. - **Reimbursement and guidance risk in the UK** [high] — NICE or NHS changes could alter access, pricing, or funding for gammaCore under the MTFM program. - **E-commerce marketplace dependency** [medium] — Truvaga sales rely on online marketplaces that can suspend listings or classify products as regulated medical devices. - **Financing and covenant constraints** [high] — The company has recurring losses and debt arrangements can restrict operating flexibility and asset use. - Heavy dependence on VA, DoD and NHS procurement decisions - Reimbursement or guidance changes can reduce prescription adoption - E-commerce platform removals can disrupt Truvaga sales - Competition and brand control are harder in online marketplaces - Debt covenants and financing needs can limit operating flexibility ## Accounting Revenue recognition is influenced by channel mix, including government procurement, direct sales, and distribution arrangements, which can create timing differences across quarters. Investors should also watch inventory, prepaid expenses, and the useful lives of licensed devices, because these estimates affect cost of goods sold and gross profit. As a loss-making company, valuation of marketable securities, deferred tax items, and any asset impairment or financing-related accounting judgments can also move reported results. - **Revenue recognition by channel** — Quarterly revenue comparability - **Estimated useful lives of licensed devices** — Gross margin and depreciation/amortization - **Inventory valuation** — Cost of goods sold and working capital - **Debt and covenant accounting** — Liquidity presentation and going-concern assessment - Revenue timing varies by government, distributor and DTC channel - Product mix affects gross margin and device useful-life estimates - Inventory and prepaid balances can swing with commercialization - Marketable securities and financing activities affect cash and income - Loss carryforwards and valuation allowances may affect tax reporting --- *Last updated: 2026-04-29T05:12:14.316958+00:00*